Latest & greatest articles for proton pump inhibitors

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on proton pump inhibitors or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on proton pump inhibitors and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for proton pump inhibitors

1. Proton pump inhibitors: increased risk of severe covid-19

Proton pump inhibitors: increased risk of severe covid-19 Prescrire IN ENGLISH - Spotlight ''Proton pump inhibitors: increased risk of severe covid-19'', 15 September 2020 {1} {1} {1} | | > > > Proton pump inhibitors: increased risk of severe covid-19 Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |   |   |   |  Spotlight Proton pump inhibitors: increased risk of severe (...) covid-19 NEWS UPDATE Proton pump inhibitors (PPIs) are known to increase the risk of various infections, including pneumonia and pseudomembranous colitis. What about covid-19 infection? A recent study yields some useful information. In 2020, a South Korean group investigated a possible association between proton pump inhibitor (PPI) exposure and severity of covid-19 in a cohort of adults who tested positive for Sars-CoV-2. The study included 132 316 patients (average age: 48 years) who had had a PCR

2020 Prescrire

2. Proton pump inhibitors for chronic obstructive pulmonary disease. (Abstract)

Proton pump inhibitors for chronic obstructive pulmonary disease. Chronic obstructive pulmonary disease (COPD) is a common and progressive disease characterised by chronic cough, airflow limitation and recurrent exacerbations. Since COPD exacerbations are linked to rising mortality and reduced quality of life, the condition poses a substantial burden on individuals, society and the healthcare system. Effective management of COPD exacerbations that includes treatment of related conditions (...) in people with COPD is thus recognised as a relevant clinical question and an important research topic. Gastroesophageal reflux disease (GERD) is a known comorbidity of COPD, and pulmonary microaspiration of gastric acid is thought to be a possible cause of COPD exacerbations. Therefore, reducing gastric acid secretion may lead to a reduction in COPD exacerbations. Proton pump inhibitors (PPIs) are one of the most commonly prescribed medications and are recommended as first-line therapy for people

2020 Cochrane

3. Intravenous proton pump inhibitors for gastric anti-secretory treatment when oral therapies are unsuitable

Intravenous proton pump inhibitors for gastric anti-secretory treatment when oral therapies are unsuitable 1 Driving better decision-making in healthcare Intravenous proton pump inhibitors for gastric anti-secretory treatment when oral therapies are unsuitable Technology Guidance from the MOH Drug Advisory Committee Published on 1 April 2020 Guidance recommendations The Ministry of Health’s Drug Advisory Committee has recommended: ? ? omeprazole 40 mg injection; and ? pantoprazole 40 mg (...) 1.2 1.3 The MOH Drug Advisory Committee (“the Committee”) considered the evidence presented for the technology evaluation of intravenous proton pump inhibitors (IV PPIs) for gastric anti-secretory treatment. The Agency for Care Effectiveness conducted the evaluation in consultation with clinical experts from public healthcare institutions. Published clinical and economic evidence for IV omeprazole, esomeprazole and pantoprazole was considered in line with their registered indications. The evidence

2020 Appropriate Care Guides, Agency for Care Effectiveness (Singapore)

4. Effect of Stress Ulcer Prophylaxis With Proton Pump Inhibitors vs Histamine-2 Receptor Blockers on In-Hospital Mortality Among ICU Patients Receiving Invasive Mechanical Ventilation: The PEPTIC Randomized Clinical Trial. (Abstract)

Effect of Stress Ulcer Prophylaxis With Proton Pump Inhibitors vs Histamine-2 Receptor Blockers on In-Hospital Mortality Among ICU Patients Receiving Invasive Mechanical Ventilation: The PEPTIC Randomized Clinical Trial. Proton pump inhibitors (PPIs) or histamine-2 receptor blockers (H2RBs) are often prescribed for patients as stress ulcer prophylaxis drugs in the intensive care unit (ICU). The comparative effect of these drugs on mortality is unknown.To compare in-hospital mortality rates (...) not significantly different by treatment group. One adverse event (an allergic reaction) was reported in 1 patient in the PPI group.Among ICU patients requiring mechanical ventilation, a strategy of stress ulcer prophylaxis with use of proton pump inhibitors vs histamine-2 receptor blockers resulted in hospital mortality rates of 18.3% vs 17.5%, respectively, a difference that did not reach the significance threshold. However, study interpretation may be limited by crossover in the use of the assigned

2020 JAMA

5. Dyspepsia - proven GORD: Proton pump inhibitors

Dyspepsia - proven GORD: Proton pump inhibitors Proton pump inhibitors | Prescribing information | Dyspepsia - proven GORD | CKS | NICE Search CKS… Menu Proton pump inhibitors Dyspepsia - proven GORD: Proton pump inhibitors Last revised in April 2017 Proton pump inhibitors Choice of proton pump inhibitor Table 1 shows the recommended doses of proton pump inhibitors (PPIs) for the management of people with gastro-oesophageal reflux disease (GORD) and severe oesophagitis. Table 1 . PPI doses (...) to be dose-equivalent to other PPIs. ‡ This dose is recommended for double dose, because the 20 mg dose of esomeprazole is considered to be equivalent to omeprazole 20 mg. Data from: [ ] Contraindications and cautions Proton pump inhibitors (PPIs) should not be prescribed to people: With alarm symptoms before endoscopy, as PPIs may mask the symptoms of upper gastrointestinal malignancy. If the person is already taking a PPI and subsequently needs an endoscopy, the PPI should be stopped at least 2 weeks

2020 NICE Clinical Knowledge Summaries

6. The overuse of proton pump inhibitors: implications for prescribing physicians

. Fossmark R, Johnsen G, Johanessen E, Waldum HL. Rebound acid hypersecretion after long-term inhibition of gastric acid secretion. Alimentary pharmacology & therapeutics. 2005;21(2):149-154. Heidelbaugh JJ, Kim AH, Chang R, Walker PC. Overutilization of proton-pump inhibitors: what the clinician needs to know. Therapeutic Advances in Gastroenterology. 2012;5(4):219-232. Ksiadzyna D, Szelag A, Paradowski L. Overuse of proton pump inhibitors. Polskie Archiwum Medycyny Wewnetrznej. 2015;125(4):289-298 (...) The overuse of proton pump inhibitors: implications for prescribing physicians The Overuse of Proton Pump Inhibitors: Implications for Prescribing Physicians – Clinical Correlations Search The Overuse of Proton Pump Inhibitors: Implications for Prescribing Physicians October 15, 2019 7 min read By Matthew Kingery Peer Reviewed Proton pump inhibitors (PPIs), frequently prescribed for dyspepsia and other acid-related disorders, are one of the most commonly used medications in the US. As of 2012

2019 Clinical Correlations

7. Safety of Proton Pump Inhibitors Based on a Large, Multi-Year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin Full Text available with Trip Pro

Safety of Proton Pump Inhibitors Based on a Large, Multi-Year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin Proton pump inhibitors (PPIs) are effective at treating acid-related disorders. These drugs are well tolerated in the short term, but long-term treatment was associated with adverse events in observational studies. We aimed to confirm these findings in an adequately powered randomized trial.We performed a 3 × 2 partial factorial double-blind trial of 17,598 participants

2019 EvidenceUpdates

8. Estimates of all cause mortality and cause specific mortality associated with proton pump inhibitors among US veterans: cohort study. Full Text available with Trip Pro

Estimates of all cause mortality and cause specific mortality associated with proton pump inhibitors among US veterans: cohort study. To estimate all cause mortality and cause specific mortality among patients taking proton pump inhibitors (PPIs).Longitudinal observational cohort study.US Department of Veterans Affairs.New users of PPIs (n=157 625) or H2 blockers (n=56 842).All cause mortality and cause specific mortality associated with taking PPIs (values reported as number of attributable

2019 BMJ

9. Trends in utilization of proton pump inhibitors in British Columbia

to the upper gastrointestinal tract, a common presentation to the primary care physi- cian. 1-3 These Letters reviewed evidence about H 2 -block- ers, eradication of Helicobacter pylori, and drugs used for gastroesophageal reflux. However, they also raised concerns about chronic acid suppression by daily dosing of omeprazole, the first proton pump inhibitor (PPI) on the Canadian market. By 1994 there was already concern that long-term proton pump inhibition could be problem- atic. Since (...) Trends in utilization of proton pump inhibitors in British Columbia Trends in utilization of proton pump inhibitors in British Columbia February - March 2019 Mailing Address: Therapeutics Initiative The University of British Columbia Department of Anesthesiology, Pharmacology & Therapeutics 2176 Health Sciences Mall Vancouver, BC Canada V6T 1Z3 Tel.: 604 822 0700 Fax: 604 822 0701 E-mail: info@ti.ubc.ca www.ti.ubc.ca 118 T he first three Therapeutics Letters focused on com - plaints related

2019 Therapeutics Letter

10. Proton pump inhibitors: increased mortality

Proton pump inhibitors: increased mortality Prescrire IN ENGLISH - Spotlight ''Proton pump inhibitors: increased mortality'', 1 January 2019 {1} {1} {1} | | > > > Proton pump inhibitors: increased mortality Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |   |   |   |  Spotlight Proton pump inhibitors: increased mortality FEATURED REVIEW Proton pump inhibitors (PPIs (...) ) such as omeprazole are used in oesophagitis, gastroesophageal reflux disease and peptic ulcer disease. PPIs have few severe adverse effects in the short term. But this is not the case in the long term. Full review (3 pages) available for download by subscribers. Abstract Proton pump inhibitors (PPIs) are widely used in oesophagitis, gastroesophageal reflux disease and peptic ulcer disease. They provoke few severe adverse effects in the short term, but this is not the case in the long term (infections, fractures

2019 Prescrire

11. Canadian Association of Gastroenterology Statement on the Putative Link Between Proton Pump Inhibitor Treatment and Gastric Cancer after Helicobacter pylori Eradication

Canadian Association of Gastroenterology Statement on the Putative Link Between Proton Pump Inhibitor Treatment and Gastric Cancer after Helicobacter pylori Eradication © The Author(s) 2018. Published by Oxford University Press on behalf of the Canadian Association of Gastroenterology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com. 1 Editorial Canadian Association of Gastroenterology Statement on the Putative Link Between Proton Pump Inhibitor T reatment (...) and Gastric Cancer after Helicobacter pylori Eradication A recent paper by Cheung et al. (1) reported that long-term use of proton pump inhibitors (PPIs) was associated with an increased risk of gastric cancer “even after” Helicobacter pylori (H. pylori) eradication. This has created significant concerns among physicians and patients (2). The Canadian Association of Gastroenterology (CAG) has serious reservations about the validity of this study and, hence, considers it important to provide guidance

2019 Canadian Association of Gastroenterology

12. Ankylosing spondylitis: Proton pump inhibitors (PPIs) for gastroprotection

Ankylosing spondylitis: Proton pump inhibitors (PPIs) for gastroprotection Proton pump inhibitors (PPIs) | Prescribing information | Ankylosing spondylitis | CKS | NICE Search CKS… Menu Proton pump inhibitors (PPIs) Ankylosing spondylitis: Proton pump inhibitors (PPIs) for gastroprotection Last revised in May 2019 Proton pump inhibitors (PPIs) for gastroprotection What issues should I consider before prescribing a proton pump inhibitor? For more information on prescribing proton pump (...) inhibitors in association with a nonsteroidal anti-inflammatory drug, see the CKS topic on . © .

2019 NICE Clinical Knowledge Summaries

13. Association of Oral Anticoagulants and Proton Pump Inhibitor Cotherapy With Hospitalization for Upper Gastrointestinal Tract Bleeding. Full Text available with Trip Pro

Association of Oral Anticoagulants and Proton Pump Inhibitor Cotherapy With Hospitalization for Upper Gastrointestinal Tract Bleeding. Anticoagulant choice and proton pump inhibitor (PPI) cotherapy could affect the risk of upper gastrointestinal tract bleeding, a frequent and potentially serious complication of oral anticoagulant treatment.To compare the incidence of hospitalization for upper gastrointestinal tract bleeding in patients using individual anticoagulants with and without PPI

2018 JAMA

14. Core IM: 5 pearls on proton pump inhibitors

Core IM: 5 pearls on proton pump inhibitors Core IM: 5 Pearls on PPIs – Clinical Correlations Search Core IM: 5 Pearls on PPIs August 29, 2018 15 min read Podcast: | Subscribe: | By Cary Blum MD, Marty Fried MD and Shreya P. Trivedi MD || Illustration by Michael Shen MD. Quiz yourself on the 5 Pearls we will be covering: What are associated adverse effects for patients are on long-term PPIs? (2:02) What are some strategies to get your patient off PPIs? (10:57) How do histamine-2 (H2) receptor (...) have a great graphic of the physiology that might be helpful to follow along with on any of our social media C: Great. So remember that gastric acid is secreted by what cells? M: Umm… Stomach cells? C: Ummm, yes… but more specifically [pause for beat] parietal cells [M: ahhhhh]. They have the hydrogen-potassium ATPase – otherwise known as… S: the proton pump! C: That’s right! The infamous proton pump – purveyor of agida, head honcho of heartburn, the regal ruler of the reflux regime, the- you guys

2018 Clinical Correlations

15. Proton pump inhibitors

Proton pump inhibitors Top results for proton pump inhibitors - Trip Database or use your Google+ account Liberating the literature ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look (...) like (#1 or #2) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for proton pump inhibitors The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials

2018 Trip Latest and Greatest

16. Deprescribing Proton Pump Inhibitors

Deprescribing Proton Pump Inhibitors Deprescribing Proton Pump Inhibitors March - April 2018 Mailing Address: Therapeutics Initiative The University of British Columbia Department of Anesthesiology, Pharmacology & Therapeutics 2176 Health Sciences Mall Vancouver, BC Canada V6T 1Z3 Tel.: 604 822 0700 Fax: 604 822 0701 E-mail: info@ti.ubc.ca www.ti.ubc.ca 111 T he first PPI was approved in Canada in 1988. Pronounced and durable reduction of stomach acid production made omeprazole a “blockbuster (...) Inhibitors. Therapeutics Letter. 2016 (Mar-Apr); 99:1-2. 10. Gomm W , von Holt K, Thom F et al. Association of Proton Pump Inhibitors With Risk of Dementia: A Pharmacoepidemiological Claims Data Analysis. JAMA Neurol. 2016;73(4):410-6. DOI:10.1001/jamaneurol.2015.4791 11. Filion KB, Chateau D, Targownik LE et al. Proton pump inhibitors and the risk of hospitalization for community-acquired pneumonia: replicated cohort studies with meta-analysis. Gut 2014; 63(4):552-558. DOI:10.1136/gutjnl-2013-304738 12

2018 Therapeutics Letter

17. Proton-Pump Inhibitors and Long-Term Risk of Community-Acquired Pneumonia in Older Adults Full Text available with Trip Pro

Proton-Pump Inhibitors and Long-Term Risk of Community-Acquired Pneumonia in Older Adults To estimate associations between long-term use of proton pump inhibitors (PPIs) and pneumonia incidence in older adults in primary care.Longitudinal analyses of electronic medical records.England PARTICIPANTS: Individuals aged 60 and older in primary care receiving PPIs for 1 year or longer (N=75,050) and age- and sex-matched controls (N=75,050).Net hazard ratios for pneumonia incidence in Year 2

2018 EvidenceUpdates

18. No Increase in Risk of Acute Myocardial Infarction in Privately Insured Adults Prescribed Proton Pump Inhibitors vs Histamine-2 Receptor Antagonists (2002-2014) Full Text available with Trip Pro

No Increase in Risk of Acute Myocardial Infarction in Privately Insured Adults Prescribed Proton Pump Inhibitors vs Histamine-2 Receptor Antagonists (2002-2014) Proton pump inhibitors (PPIs) are commonly used medications. Recent studies reported an increased risk of acute myocardial infarction (MI) in PPI users vs non-users. We evaluated MI risk associated with PPIs compared with histamine-2 receptor antagonists (H2RAs) in privately insured adults in the United States.Using administrative

2018 EvidenceUpdates

19. Proton Pump Inhibitors: Are They a Real Threat to the Patient? Full Text available with Trip Pro

Proton Pump Inhibitors: Are They a Real Threat to the Patient? Proton pump inhibitors are among the most frequently prescribed drugs in the world and are generally considered safe. However, there is growing concern regarding their safety.A nonsystematic review of the current literature was performed regarding proton pump inhibitors and their adverse effects. Proton pump inhibitors seem to be associated with fundic gland polyp development (without clinical relevance) and Clostridium difficile (...) infection. Also, in cirrhotic patients, their prescription should be carefully reviewed. Regarding their association with other enteric infections, micronutrient deficiency, dementia, and chronic kidney disease, current evidence is still of low quality, and further studies are needed.Considering the current evidence, most patients with a clear clinical indication for proton pump inhibitor treatment should probably benefit from the maintenance of their treatment without significant adverse effects

2018 GE Portuguese journal of gastroenterology

20. General medicine: Proton pump inhibitor therapy after Helicobacter pylori eradication may increase the risk of gastric cancer

General medicine: Proton pump inhibitor therapy after Helicobacter pylori eradication may increase the risk of gastric cancer Proton pump inhibitor therapy after Helicobacter pylori eradication may increase the risk of gastric cancer | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your (...) username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Proton pump inhibitor therapy after Helicobacter pylori eradication may increase the risk of gastric cancer Article Text Commentary General medicine

2018 Evidence-Based Medicine